What African Patients, Clinicians, and Regulators Can Gain from Pharmacometrics: Forecasts for the Future in a New Era in HealthCLINICAL PHARMACOLOGY & THERAPEUTICSIF5.52025-12-010PRE
Advancing pharmacometrics in Africa-Transition from capacity development toward job creationCPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGYIF32024-12-090OA
A Modern Curriculum for Training Scientists in Model-Informed Drug Development: Progress Report on FDA Grant to Train Regulatory ScientistsCLINICAL PHARMACOLOGY & THERAPEUTICSIF5.52024-07-161OAAI
Use of RWE to Inform Regulatory, Public Health Policy, and Intervention Priorities for the Developing WorldCLINICAL PHARMACOLOGY & THERAPEUTICSIF5.52021-10-3113OAAI
Scientific considerations for global drug developmentSCIENCE TRANSLATIONAL MEDICINEIF14.62020-07-298OAAI
Time to Step Up: A Call to Action For the Clinical and Quantitative Pharmacology Community to Accelerate Therapeutics for COVID-19CTS-CLINICAL AND TRANSLATIONAL SCIENCEIF2.82020-06-114OAAI
Leveraging crowdsourcing to accelerate global health solutionsNATURE BIOTECHNOLOGYIF41.72019-07-198OAAI
Drug-Drug Interactions of Infectious Disease Treatments in Low-Income Countries: A Neglected Topic?CLINICAL PHARMACOLOGY & THERAPEUTICSIF5.52019-03-217OAAI
Model-Informed Assessment of Anti-Infectives for Young Children in Low- and Middle-Income CountriesCPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGYIF32019-02-271OAAI
In Vitro and In Vivo Activity of Amiodarone Against Ebola Virus胺碘酮对埃博拉病毒的体内外活性JOURNAL OF INFECTIOUS DISEASESIF4.52018-07-1613OAAI
Model-Informed Drug Development for Malaria Therapeutics用于疟疾治疗的模型知情药物开发ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGYIF02018-01-0625OAAI
Beyond open data: realising the health benefits of sharing dataBMJ-BRITISH MEDICAL JOURNALIF42.72016-10-1048OAAI
Data Sharing and Inductive Learning - Toward Healthy Birth, Growth, and DevelopmentNEW ENGLAND JOURNAL OF MEDICINEIF78.52016-06-2316OAAI
Ebola viral load at diagnosis associates with patient outcome and outbreak evolution诊断时的埃博拉病毒载量与患者结局和爆发演变有关JOURNAL OF CLINICAL INVESTIGATIONIF13.62015-11-09108OA
Effect of a Pluronic® P123 Formulation on the Nitric Oxide-Generating Drug JS-KPHARMACEUTICAL RESEARCHIF4.32014-10-1814OAAI
Modeling Viral Kinetics and Treatment Outcome During Alisporivir Interferon-Free Treatment in Hepatitis C Virus Genotype 2 and 3 PatientsHEPATOLOGYIF15.82014-05-0124PREAI
MODELING EARLY VIRAL KINETICS WITH ALISPORIVIR: INTERFERON-FREE TREATMENT AND SVR PREDICTIONS IN HCV G2/3 PATIENTSJOURNAL OF HEPATOLOGYIF332013-04-010OAAI
Pharmacokinetic Evaluation of the Penetration of Antituberculosis Agents in Rabbit Pulmonary LesionsANTIMICROBIAL AGENTS AND CHEMOTHERAPYIF4.52012-01-01154OAAI
Comparison between cerebral state index and bispectral index as measures of electroencephalographic effects of sevoflurane using combined sigmoidal Emax model应用s形Emax复合模型比较脑状态指数与脑电双频指数对七氟醚脑电效应的影响ACTA PHARMACOLOGICA SINICAIF8.42011-09-056OA
Modeling the Effect of Sevoflurane on Corrected QT Prolongation A Pharmacodynamic AnalysisANESTHESIOLOGYIF9.12010-10-0127OA